New published article: Robaux et al., 2023

Congratulations to Pr. Beauloye and colleagues on the publication in the journal Platelets of their article on the link between dual antiplatelet therapy and α-tubulin acetylation. We are proud to have contributed to the success of this article!

𝐃𝐮𝐚𝐥 𝐚𝐧𝐭𝐢𝐩𝐥𝐚𝐭𝐞𝐥𝐞𝐭 𝐭𝐡𝐞𝐫𝐚𝐩𝐲 (DAT), combining aspirin and a P2Y12 receptor inhibitor, is the main treatment to prevent atherothrombotic complications. In some patients, 𝐡𝐢𝐠𝐡 𝐨𝐧-𝐭𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭 𝐩𝐥𝐚𝐭𝐞𝐥𝐞𝐭 𝐫𝐞𝐚𝐜𝐭𝐢𝐯𝐢𝐭𝐲 persists due to poor treatment response. Tubulin acetylation is responsible for the 𝐝𝐢𝐬𝐜𝐨𝐢𝐝 𝐦𝐨𝐫𝐩𝐡𝐨𝐥𝐨𝐠𝐲 𝐨𝐟 𝐫𝐞𝐬𝐭𝐢𝐧𝐠 𝐩𝐥𝐚𝐭𝐞𝐥𝐞𝐭𝐬. The authors investigated the link 𝐛𝐞𝐭𝐰𝐞𝐞𝐧 𝐚𝐧𝐭𝐢𝐩𝐥𝐚𝐭𝐞𝐥𝐞𝐭 𝐭𝐡𝐞𝐫𝐚𝐩𝐲 𝐚𝐧𝐝 α-𝐭𝐮𝐛𝐮𝐥𝐢𝐧 𝐚𝐜𝐞𝐭𝐲𝐥𝐚𝐭𝐢𝐨𝐧.

Platelets from 240 patients were studied and the 𝐥𝐞𝐯𝐞𝐥 𝐨𝐟 α-𝐭𝐮𝐛𝐮𝐥𝐢𝐧 𝐚𝐜𝐞𝐭𝐲𝐥𝐚𝐭𝐢𝐨𝐧 was assessed. The results showed that α-tubulin acetylation was 𝐢𝐧𝐜𝐫𝐞𝐚𝐬𝐞𝐝 𝐢𝐧 𝐩𝐚𝐭𝐢𝐞𝐧𝐭𝐬 𝐭𝐫𝐞𝐚𝐭𝐞𝐝 𝐰𝐢𝐭𝐡 𝐃𝐓𝐀. In addition, the proportion of patients with high levels of α-tubulin acetylation was reduced among DAT-treated patients with high on-treatment platelet reactivity. The study therefore highlighted the fact that a high level of α-tubulin acetylation is a 𝐦𝐚𝐫𝐤𝐞𝐫 𝐨𝐟 𝐩𝐥𝐚𝐭𝐞𝐥𝐞𝐭 𝐢𝐧𝐡𝐢𝐛𝐢𝐭𝐢𝐨𝐧 in response to DAT.

This article offers a 𝐬𝐭𝐞𝐩 𝐟𝐨𝐫𝐰𝐚𝐫𝐝 in understanding the response to DAT. Future work will certainly address the question of the effect of α-tubulin acetylation in response to DAT 𝐨𝐧 𝐩𝐥𝐚𝐭𝐞𝐥𝐞𝐭 𝐦𝐨𝐫𝐩𝐡𝐨𝐥𝐨𝐠𝐲. The article is already 𝐚𝐯𝐚𝐢𝐥𝐚𝐛𝐥𝐞 𝐨𝐧 𝐭𝐡𝐞 𝐣𝐨𝐮𝐫𝐧𝐚𝐥'𝐬 𝐰𝐞𝐛𝐬𝐢𝐭𝐞! DOI: 10.1080/09537104.2023.2250002